The executive director of Canada’s drug pricing regulator is stepping down—just days after another member resigned because of concerns that the federal government was undermining the regulator’s work. Douglas Clark, executive director of the Patented Medicine Prices Review Board, announced today he will be leaving his post after almost a decade with the regulator. On…
Head of Canada’s Drug Price Regulator Resigns Same Week as Colleague Steps Down
New Alzheimer’s Treatment Would Cost $26,500 Per Year
A new Alzheimer’s treatment would cost patients an estimated $26,500 per year, said the drug developer. The Food and Drug Administration (FDA) announced on Jan. 6 that it would grant accelerated approval to Biogen and Eisai, after the drug appeared to partially slow the development of mild cases of Alzheimer’s disease in clinical trials. The same day, Eisai submitted…
Liberals Delay New Regulations to Lower Price of Medicines in Canada
OTTAWA—Health Minister Jean-Yves Duclos has put a six-month pause on new regulations designed to lower the cost of patented medicines in Canada. Health Canada first announced the changes in 2019 to protect Canadians from excessive drug prices, but the government has repeatedly delayed implementing the rules. The regulations were supposed to come into force at…
-
Recent Posts
-
Archives
- May 2025
- April 2025
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- September 2013
- July 2013
- March 2013
- January 2013
- December 2012
- November 2012
- December 1
-
Meta